4.5 Article

Designing Anticancer Peptides by Constructive Machine Learning

Journal

CHEMMEDCHEM
Volume 13, Issue 13, Pages 1300-1302

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201800204

Keywords

artificial intelligence; de novo design; deep learning; drug discovery; peptide design

Funding

  1. Swiss National Science Foundation [CRSII2_160699, 200021_157190, IZSEZ0_177477]
  2. Swiss National Science Foundation (SNF) [IZSEZ0_177477, 200021_157190, CRSII2_160699] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Constructive (generative) machine learning enables the automated generation of novel chemical structures without the need for explicit molecular design rules. This study presents the experimental application of such a deep machine learning model to design membranolytic anticancer peptides (ACPs) de novo. A recurrent neural network with long short-term memory cells was trained on -helical cationic amphipathic peptide sequences and then fine-tuned with 26 known ACPs by transfer learning. This optimized model was used to generate unique and novel amino acid sequences. Twelve of the peptides were synthesized and tested for their activity on MCF7 human breast adenocarcinoma cells and selectivity against human erythrocytes. Ten of these peptides were active against cancer cells. Six of the active peptides killed MCF7 cancer cells without affecting human erythrocytes with at least threefold selectivity. These results advocate constructive machine learning for the automated design of peptides with desired biological activities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available